Back to LCT Homepage Targeting Huntington's Disease, Stroke, Type 1 Diabetes and Haemophilia
Information about LCT Living Cell Technologies
LCT - Living Cell Technologies
News updates: Subscribe
Unsubscribe


June 5, 2008
LCT Expands Diabetes Clinical Trial
June 3, 2008
LCT Lists on International OTCQX
May 21, 2008
LCT interviewed by New Zealand TV program, Close Up
May 12, 2008
LCT presents encapsulation technology at conference
May 8, 2008
LCT features on Channel Ten News
May 8, 2008
LCT prepares to list on international OTCQX
 

Diabetes

Diabetes is a chronic disease characterised by high blood glucose levels resulting from the body not producing insulin or using it properly. Insulin is a hormone needed for glucose to enter the cells and be converted to energy.

There are two main types of diabetes. Type 1 diabetes occurs when the pancreas gland no longer produces the insulin needed. It is usually diagnosed in childhood or early adulthood and is one of the most common chronic childhood diseases in developed nations. The most common form of diabetes is Type 2. In Type 2 diabetes, the body either doesn’t produce enough insulin or the cells ignore the insulin produced. The buildup in glucose in the blood deprives the cells of energy and over time impacts eye, kidney, nerve or heart functioning.

Regular treatment usually consists of lifelong insulin injections every day, regular blood glucose level tests, healthy eating plans and physical activity.

LCT aims to treat Type 1 diabetes. Healthy islet cells are algae coated capsules and transplanted into the body to produce insulin and regulate blood glucose levels. The capsules ensure that the cells are not recognised as foreign by the patient, so no immunosuppressant drugs are needed.

  • It is estimated that around 194 million people have diabetes in the adult population in the IDF Regions (an increase from the 1995 global estimation of 135 million published in a World Health Organization study in 1998)
  • Type 1 diabetes represents 10 to 15% of all cases
  • It is estimated that approximately 4.9 million people (in all age groups) have type 1 diabetes. The European region has the highest estimated number of people with type 1 diabetes (1.27 million), followed by the North American Region (1.04 million) and the South East Asian Region (0.91 million).
  • Diabetes is Australia’s fastest growing chronic disease
  • 520,000 Australians are diagnosed with diabetes. According to Diabetes Australia, for every one who knows they have it, another has it but doesn’t know
  • The World Health Organization (WHO) estimates that 2.5 to 15% of annual health budgets are spent on diabetes-related illnesses
  • A person with diabetes incurs medical costs that are two to five times higher than those of a person without diabetes. This is due to more frequent medical visits, purchase of supplies and medication, and the higher likelihood of being admitted to a hospital.
LCT - Living Cell Technologies
What is xenotransplantation?
The use of living animal cells, tissues or organs in human therapeutics. >more

What is DiabeCell?
DiabeCell is a porcine pancreatic cell product for the treatment of insulin-dependent diabetes. >more

What is NeurotrophinCell?
A choroid plexus (brain) cell product with the potential to treat diseases of the nervous system such as Huntington's disease and stroke. >more

What is LCT's encapsulation technology?
The living cells are covered in a seaweed-derived coating (alginate encapsulation) to form capsules which eliminate the
need for toxic immunosuppressant drugs and allow the release of beneficial factors.
>more
   
graphic design and website design - PDF Communications Ltd